3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Melanoma
12
Colorectal Neoplasms
8
Lung Neoplasms
7
Ovarian Neoplasms
6
Neoplasms
5
Mesothelioma, Malignant
5
Carcinoma, Renal Cell
5
Breast Neoplasms
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Carcinoma, Merkel Cell
4
Uterine Cervical Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Skin Neoplasms
2
Sarcoma
2
Recurrence
2
Prostatic Neoplasms
2
Pleural Effusion, Malignant
2
Lymphoma
2
Endometrial Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Hepatocellular
2
Adenocarcinoma of Lung
2
Uveal Melanoma
1
Interventions
fludarabine
3
aldesleukin
3
Cyclophosphamide
3
vedolizumab
2
atezolizumab
2
Riluzole
2
LDP-02
2
Infliximab
2
Immunoglobulin G
2
Fecal Microbiota Transplantation
2
Disulfides
2
CT-P13
2
prednylidene
1
pembrolizumab
1
motexafin gadolinium
1
deltacortene
1
Tinzaparin
1
Therapeutics
1
Taste
1
Standard of Care
1
Radiotherapy
1
Prednisone
1
Practice Guidelines as Topic
1
Loperamide
1
Interleukin-2
1
Immunotherapy
1
Geriatric Assessment
1
Fatty Acids, Omega-3
1
Exercise
1
Endoscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Interleukin-2
×
Thoracic
×
Clear all
NCT05902520
2026-01-08
ACT
AgonOx, Inc.
Phase 1
Active not recruiting
18 enrolled